| Active, not recruiting | 2 | 400 | US | Pfizer-BioNTech COVID-19 Vaccine 2023-2024, mRNA COVID-19 vaccine, BNT162b2 mRNA COVID-19 vaccine, SARS-CoV-2 RNA vaccine, Comirnaty, Moderna COVID-19 Vaccine 2023-2024, Moderna COVID-19 vaccine, SARS-CoV-2 vaccine, Spikevax, SOC IS Regimen, Standard of Care transplant immunosuppression regimen, Immunosuppression (IS), mycophenolate mofetil (MMF) or equivalent, tacrolimus, SOC IS Reduction, Standard of Care (SOC) transplant immunosuppression regimen, Immunosuppression (IS) Reduction | National Institute of Allergy and Infectious Diseases (NIAID), PPD, Johns Hopkins University | Kidney Transplant Recipients, Liver Transplant Recipients | 02/24 | 03/25 | | |
RSV OA=ADJ-023, NCT05921903: A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above |
|
|
| Active, not recruiting | 2 | 387 | Europe, Canada, Japan, US, RoW | RSVPreF3 OA Investigational Vaccine | GlaxoSmithKline | Respiratory Syncytial Virus Infections | 07/24 | 06/25 | | |
